N-Acetyl-L-Leucine - IntraBio
Alternative Names: IB-1001 - IntraBioLatest Information Update: 11 Jun 2024
At a glance
- Originator University of Munich; University of Oxford
- Developer IntraBio
- Class Acetamides; Amino acids; Esters; Neuroprotectants; Pentanoic acids; Small molecules; Vestibular disorder therapies
- Mechanism of Action Calcium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Niemann-Pick disease type C
- Phase II Ataxia telangiectasia; Sandhoff disease; Tay-Sachs disease
Most Recent Events
- 13 Apr 2024 Efficacy and adverse events data from a phase III trial in Niemann-Pick disease type C presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 14 Aug 2023 IntraBio plans to file for marketing authorization with N-Acetyl-L-Leucine with the US FDA and EMA
- 14 Aug 2023 Efficacy and adverse events data from a phase III trial in Niemann-Pick disease type C released by IntraBio